Brand Murray Fuller patent opposition analysis

The comprehensive analysis of Brand Murray Fuller opposition landscape, with a particular emphasis on intellectual property (IP) dynamics.

Stay updated with the latest patent oppositions filed by Brand Murray Fuller

Patent NumberTitleApplicantOpposition DateOpposition Company
Use Of Migalostat In Reducing The Risk Of Cerebrovascular Event In Patients With Fabry DiseaseAMICUS THERAPEUTICSAug 13, 2025BRAND MURRAY FULLER
Use Of Long-Acting Glp-1 PeptidesNOVO NORDISKAug 10, 2025ADALVO
Anticancer CompositionsARAGON PHARMACEUTICALSJul 9, 2025BRAND MURRAY FULLER
Methods Of Treating Fabry Patients Having Renal ImpairmentAMICUS THERAPEUTICSJul 9, 2025BRAND MURRAY FULLER
Uses For And Article Of Manufacture Including Her2 Dimerization Inhibitor PertuzumabF HOFFMANN LA ROCHEJun 18, 2025BRAND MURRAY FULLER
Methods Of Treating New-Onset Plaque Type Psoriasis Using Il-17 AntagonistsNOVARTISMay 21, 2025BRAND MURRAY FULLER
Treatment Of Sepsis And Septic ShockCOMBIOXINMay 6, 2025BRAND MURRAY FULLER
Methods Of Treating Fabry Disease In Patients Having A Mutation In The Gla GeneAMICUS THERAPEUTICSApr 24, 2025BRAND MURRAY FULLER
Manufacture Of DegarelixFERRINGApr 10, 2025ACCORD HEALTHCARE
Methods For Treating Atopic Dermatitis By Administering An Il-4R AntagonistSANOFI BIOTECHNOLOGYJan 24, 2025BRAND MURRAY FULLER